Novel therapeutics
targeting
diseases of aging

RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

Transforming stem cell
transplant therapy for auto-
immune and blood-based diseases

Precision therapeutics for
genetically-defined age-related
macular degeneration and rare diseases

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)

Proprietary pharmaceuticals for
neonatal care and pediatrics –
Sold to Mallinckrodt Aug 2017

Universal cell-based
cancer immunotherapy
IPO Mar 2018 (NASDAQ: UMRX)

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007

Preventing axonal degeneration
in patients with
neurological diseases

New class of
regulated cell and
gene therapies

Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

Cell and gene therapies
for rare diseases
and cancer

Cancer immunotherapies
at the interface of
innate & adaptive immunity

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

Advancing targeted protein
degradation to target previously
“undruggable” disease pathways

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

Bispecific antibodies
to improve the treatment
of serious diseases

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

Minimally invasive
heart valve
devices

Behavioral epigenetic therapy
for cognitive
and neurodegenerative disease

Novel MetAP2 therapeutics to transform
complex metabolic disorders –
IPO June 2014 (NASDAQ: ZFGN)

Novel biologic therapeutics for
autoimmune diseases – Sold to
Celgene (NASDAQ: CELG) Jan 2017

Stimulating the innate and
adaptive immune system in a
novel approach to treat cancer

Small molecule
drug design
using statistical modeling

Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

Next-generation oncolytic
immunotherapies for
cancer treatment

Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

Discovering new medicines
for severe
neurodegenerative diseases

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

Breakthrough computer-aided
drug design
for transformative medicines

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

Next generation
synthetic biology platform
for novel therapeutics

Titratable, re-dosable genetic
medicines with drug-like properties
for patients with genetic diseases

First-in-class
RNA therapies
for severe genetic diseases

Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016

Novel bicyclic peptides (bicycles)
and bicycle drug conjugates
for cancer

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

Innovative micro-RNA-
based therapies –
IPO Feb 2017 (NASDAQ: MGEN)

Precision neuroscience to
treat neurological and
neuropsychiatric disease

Tamper resistant therapies for
chronic pain – IPO Feb 2014
(NASDAQ: EGLT)

Targeting RNA-modifying
proteins for novel
precision cancer therapies

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)